@article{3020178,
    title = "Elevated MICs of susceptible antipseudomonal cephalosporins in non-carbapenemase-producing, carbapenem-resistant pseudomonas aeruginosa: Implications for dose optimization",
    author = "Gill, C.M. and Aktaş, E. and Alfouzan, W. and Bourassa, L. and Brink, A. and Burnham, C.-A.D. and Canton, R. and Carmeli, Y. and Falcone, M. and Kiffer, C. and Marchese, A. and Martinez, O. and Pournaras, S. and Seifert, H. and Thabit, A.K. and Villegas, M.V. and Westblade, L.F. and Nicolau, D.P. and Wille, J. and Rezende, T.T.F. and Cekin, Z. and Malkocoglu, G. and Gijón, D. and Tarakmeh, L.A. and Chu, C.Y. and Opperman, C.J. and Tootla, H.D. and Moodley, C. and Coetzee, J. and Vourli, S. and Dimopoulos, G. and Attallah, D.M. and Tiseo, G. and Leonildi, A. and Giordano, C. and Barnini, S. and Menichetti, F. and Di Pilato, V. and Codda, G. and Vena, A. and Giacobbe, D.R. and Satlin, M. and Cardona, A. and Curtis, L. and Fang, F. and Thomson, G. and Thomson, K. and the ERACE-PA Global Study Group",
    journal = "Antimicrobial Agents and Chemotherapy",
    year = "2021",
    volume = "65",
    number = "11",
    publisher = "American Society for Microbiology",
    issn = "0066-4804, 1098-6596",
    doi = "10.1128/AAC.01204-21",
    keywords = "cefepime;  ceftazidime;  antiinfective agent;  azabicyclo derivative;  carbapenem derivative;  ceftazidime;  cephalosporin derivative, antibiotic sensitivity;  Article;  bacterium isolate;  carbapenem resistant Pseudomonas aeruginosa;  clinical laboratory standard;  controlled study;  dose calculation;  drug potency;  in vitro study;  maximum permissible dose;  MIC50;  MIC90;  Monte Carlo method;  nonhuman;  process optimization;  human;  microbial sensitivity test;  Pseudomonas aeruginosa;  Pseudomonas infection, Anti-Bacterial Agents;  Azabicyclo Compounds;  Carbapenems;  Ceftazidime;  Cephalosporins;  Humans;  Microbial Sensitivity Tests;  Pseudomonas aeruginosa;  Pseudomonas Infections",
    abstract = "The present study evaluated the in vitro potency of ceftazidime and cefepime among carbapenem-resistant Pseudomonas aeruginosa isolates collected as part of a global surveillance program and assessed the pharmacodynamic implications using previously published population pharmacokinetics. When susceptible, MICs resulted at the high end of distribution for both ceftazidime and cefepime, thus 6 g/day was required to achieve optimal pharmacodynamic profiles. These findings should be considered in the clinic and for the application of CLSI susceptibility breakpoints. © 2021 American Society for Microbiology."
}